This site is intended for UK healthcare professionals only
This webcast series and supporting materials was developed by the Chronic Conditions faculty in conjunction with OmniaMed Communications. The sponsoring companies have had no input into the agenda, speaker selection, presentations or collateral content, with the exception of the symposium sessions, for which the respective sponsoring companies are fully responsible.

Chronic Conditions Month 2022

Cardiovascular

On-demand videos

What’s new and top tips in valve disease and AF

These video presentations were originally broadcast on the 26 May 2022.

Please note that the speakers are not able to answer questions from attendees watching the video on-demand

What’s new and top tips in HF and Angina

These video presentations were originally broadcast on the 26 May 2022.

Please note that the speakers are not able to answer questions from attendees watching the video on-demand

Chronic Conditions Month 2022

Cardiovascular

Join us for a series of interactive webinars and podcasts to help you optimise care for people with chronic conditions

The agenda

13:00-13:45

What’s new and top tips in valve disease and AF

  • Establish a diagnosis
  • Portable ECG
  • Antibiotic prophylaxis
  • Intervention options: TAVI, ablation and anticoagulation

13:45-14:20

Type 2 diabetes and cardiovascular disease: An evidence-based discussion on semaglutide in adults living with Type 2 diabetes.

This promotional symposium has been developed, organised and funded by Novo Nordisk for UK healthcare professionals only. Novo Nordisk products will be discussed.
UK22OZM00111 | May 2022
Adverse event reporting and prescribing information for Rybelsus®▼ (Semaglutide tablets), Ozempic®▼ (semaglutide) and Victoza®(liraglutide) can be accessed by clicking the relevant button below
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Stores. Adverse events should also be reported to Novo Nordisk Limited (Telephone Novo Nordisk Customer Care Centre 0800 023 2573). Calls may be monitored for training purposes.

Dr Matt Capehorn

GP with Special interest in Diabetes and Obesity, Rotherham

14:20-15:00

What’s new and top tips in HF and Angina

  • How to diagnose HFpEF
  • Treatment options in HFpEF
  • Assessment of angina
  • The (lack of) evidence: PCI for angina
  • Antianginal treatment

The speakers

Dr Yassir Javaid

Cardiovascular and Diabetes Lead, Northamptonshire CCG

Rob Hampton

Portfolio GP, Occupational Physician and GPwSI in Drug and Alcohol Treatment, Leicester

Therapy webcast sponsor

At Novo Nordisk, our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders.

Novo Nordisk is a leading global healthcare company, founded in 1923 and our heritage has given us experience and capabilities that enable us to expand access to our medicines and work to prevent and ultimately cure disease by pioneering scientific breakthroughs.

Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Every day, millions of people all over the world rely on our products.

This promotional webcast has been developed, organised and funded by Novo Nordisk. Novo Nordisk treatments may be discussed. Prescribing information will be provided at the meeting.

Adverse event reporting and prescribing information for Rybelsus®▼ (Semaglutide tablets), Ozempic®▼ (semaglutide) and Victoza®(liraglutide) can be accessed by clicking the relevant button below
chronic-conditions-logo-white
© Copyright Omniamed Communications. All Rights Reserved 108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom